244 related articles for article (PubMed ID: 24934886)
1. Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan.
Izumikawa K; Watanabe A; Miyashita N; Ishida T; Hosono H; Kushimoto S; Kohno S
J Infect Chemother; 2014 Sep; 20(9):541-8. PubMed ID: 24934886
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
Izumikawa K; Watanabe A; Miyashita N; Ishida T; Hosono H; Kushimoto S; Kohno S
J Infect Chemother; 2014 Sep; 20(9):549-57. PubMed ID: 24934887
[TBL] [Abstract][Full Text] [Related]
3. Prospective surveillance for atypical pathogens in children with community-acquired pneumonia in Japan.
Bamba M; Jozaki K; Sugaya N; Tamai S; Ishihara J; Kori T; Shiro H; Takeuchi Y; Cho H; Nakao A; Okano Y; Kimura K; Komiyama O; Nonoyama M; Kobayashi I; Kato T; Sunakawa K
J Infect Chemother; 2006 Feb; 12(1):36-41. PubMed ID: 16506088
[TBL] [Abstract][Full Text] [Related]
4. Multicenter surveillance of adult atypical pneumonia in Japan: its clinical features, and efficacy and safety of clarithromycin.
Goto H
J Infect Chemother; 2011 Feb; 17(1):97-104. PubMed ID: 21210175
[TBL] [Abstract][Full Text] [Related]
5. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
6. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
7. [Coinfection with Mycoplasma pneumoniae and Chlamydophila pneumoniae in a middle-aged adult].
Kubo T; Takigawa N; Tanimoto Y; Ichihara E; Tabata M; Miyahara N; Kanehiro A; Kiura K; Tanimoto M
Nihon Kokyuki Gakkai Zasshi; 2007 Oct; 45(10):808-11. PubMed ID: 18018632
[TBL] [Abstract][Full Text] [Related]
8. Mycoplasma pneumoniae and Chlamydophila pneumoniae in children with community-acquired pneumonia in Thailand.
Lochindarat S; Suwanjutha S; Prapphal N; Chantarojanasiri T; Bunnag T; Deerojanawong J; Kunakorn M; Srisan P
Int J Tuberc Lung Dis; 2007 Jul; 11(7):814-9. PubMed ID: 17609060
[TBL] [Abstract][Full Text] [Related]
9. Atypical pneumonia.
Basarab M; Macrae MB; Curtis CM
Curr Opin Pulm Med; 2014 May; 20(3):247-51. PubMed ID: 24626238
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Hammerschlag MR
Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473
[TBL] [Abstract][Full Text] [Related]
12. [Peculiarities of diagnostics and therapy of atypical pulmonary diseases in Russian hospital in Kosovo].
Kazakov SP; Papenko IuV; Horkay B
Voen Med Zh; 2004 Mar; 325(3):38-9. PubMed ID: 15112410
[No Abstract] [Full Text] [Related]
13. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
[TBL] [Abstract][Full Text] [Related]
15. Atypical pneumonia.
J Assoc Physicians India; 2013 Jul; 61(7 Suppl):28-31. PubMed ID: 24779155
[No Abstract] [Full Text] [Related]
16. Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations.
Meloni F; Paschetto E; Mangiarotti P; Crepaldi M; Morosini M; Bulgheroni A; Fietta A
J Chemother; 2004 Feb; 16(1):70-6. PubMed ID: 15078002
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
18. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
19. Influence of age on the clinical differentiation of atypical pneumonia in adults.
Miyashita N; Kawai Y; Akaike H; Ouchi K; Hayashi T; Kurihara T; Okimoto N
Respirology; 2012 Oct; 17(7):1073-9. PubMed ID: 22563979
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections.
Principi N; Esposito S
Lancet Infect Dis; 2001 Dec; 1(5):334-44. PubMed ID: 11871806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
